Squarepoint
TVRD

Squarepoint’s Tvardi Therapeutics TVRD Stock Holding History

Squarepoint’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Sell
32,676
-19,107
-37% -$74.9K ﹤0.01% 4062
2025
Q4 		$223K Buy
51,783
+43,619
+534% +$391K ﹤0.01% 3798
2025
Q3 		$318K Buy
+8,164
New +$232K ﹤0.01% 3618
2024
Q1 		– Sell
-1,072
Closed -$28.7K – 4724
2023
Q4 		$28.7K Buy
+1,072
New +$44.4K ﹤0.01% 3894
2023
Q2 		– Sell
-5,439
Closed -$961K – 4107
2023
Q1 		$961K Buy
+5,439
New +$1.82M ﹤0.01% 1923
2022
Q3 		– Sell
-728
Closed -$239K – 3543
2022
Q2 		$239K Buy
+728
New +$255K ﹤0.01% 2381
2022
Q1 		– Sell
-401
Closed -$176K – 3651
2021
Q4 		$176K Buy
401
+40
+11% +$20.1K ﹤0.01% 2758
2021
Q3 		$201K Buy
+361
New +$181K ﹤0.01% 2487
2021
Q2 		– Sell
-296
Closed -$232K – 3782
2021
Q1 		$232K Buy
+296
New +$203K ﹤0.01% 2607
2020
Q4 		– Sell
-868
Closed -$397K – 3326
2020
Q3 		$397K Buy
+868
New +$504K 0.01% 1610
2020
Q2 		– Sell
-311
Closed -$148K – 2567
2020
Q1 		$148K Sell
311
-863
-74% -$469K ﹤0.01% 1559
2019
Q4 		$681K Buy
1,174
+885
+306% +$621K ﹤0.01% 1577
2019
Q3 		$190K Buy
+289
New +$240K ﹤0.01% 2097
2018
Q4 		– Sell
-272
Closed -$235K – 2292
2018
Q3 		$235K Buy
+272
New +$196K ﹤0.01% 1677
2018
Q1 		– Sell
-2,460
Closed -$1.08M – 2223
2017
Q4 		$1.08M Buy
+2,460
New +$1.12M 0.02% 792
2017
Q1 		– Sell
-2,452
Closed -$820K – 1958
2016
Q4 		$820K Buy
+2,452
New +$787K 0.03% 583

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Squarepoint's TVRD Position: Q1 2026 in Review

Squarepoint reduced its Tvardi Therapeutics (TVRD) stake by 37% in Q1 2026, selling an estimated $74.9K and leaving 32,676 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4062.

Squarepoint first reported a position in TVRD in Q4 2016 and has held it in 16 quarters since. The position peaked at $1.08M in Q4 2017. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Squarepoint held 32,676 shares of Tvardi Therapeutics worth $104K as of Q1 2026.
  • Squarepoint sold 19,107 Tvardi Therapeutics shares in Q1 2026, an estimated $74.9K.
  • Tvardi Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4062 holding.
  • Squarepoint first reported a position in Tvardi Therapeutics in Q4 2016 and has held it in 16 quarters since.
  • Squarepoint's Tvardi Therapeutics position peaked at $1.08M in Q4 2017.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.